Publication: JCN Newswires
Publication Date: 04-DEC-07
Delivery: Immediate Online Access
Author:
Company: Eisai Company Ltd.

Article Excerpt
Tokyo, Japan, Dec 4, 2007 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) and BioArctic Neuroscience AB (Headquarter: Stockholm, Sweden, CEO: Par Gellerfors) announced today that on December 3, they signed an exclusive licence agreement for BAN2401, a novel humanized monoclonal antibody, which is being developed as a next-generation therapeutic treatment for Alzheimer's disease. Under the terms of the agreement Eisai obtains the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer's disease.

BAN2401 is the result of a strategic research...



NOTE: All illustrations and photos have been removed from this article.



More articles from JCN Newswires
Mazda Unveils Freshened MPV in Japan., 15-JAN-08
Panasonic 'EVOLTA' Sets Guinness World Record For the Longest Lasting AA Alkaline Battery., 15-JAN-08
Mitsubishi Corporation to Sponsor the Japanese Galleries at the British Museum., 15-JAN-08

Looking for additional articles?
Click here to search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Click here to search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.